Abstract
Results from the IDEA collaboration study indicated that the efficacy of CAPOX was better than that of FOLFOX as adjuvant chemotherapy in patients with stage III colon cancer. Although dose adjustment of capecitabine was required depending on renal function, the results from this study did not mention renal function. Here, we investigated the impact of renal function on CAPOX and FOLFOX adjuvant chemotherapy in colon cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
